Welcome to your daily round-up of everything happening in the world of neurorehabilitation.
Research news
Rice research project ‘crucial for developing effective treatments’ for amyloid diseases
A team of Rice University researchers led by Angel Martí, professor and chair of chemistry and professor of bioengineering, materials science and nanoengineering, was awarded a $1.875 million grant by the National Institutes of Health (NIH) to support its groundbreaking research in biological fibrillar nanostructures with potential implications for the treatment and diagnosis of diseases including Alzheimer’s and Parkinson’s.
Similarities in protein structures between Alzheimer’s disease and Down syndrome
A new study recently published in Nature Structural and Molecular Biology uses leading-edge cryo-electron microscopy imaging technology to determine whether differences exist between the protein structures in those with Alzheimer’s disease and those with both Alzheimer’s disease and Down syndrome.
Blocking a neural receptor responsible for addiction could reduce alcohol use
Scripps Research scientists have found that LY2444296—a compound that selectively blocks the kappa opioid receptor (KOP)—may reduce drinking in cases of alcohol dependence in animal studies. The findings, which were published March 9, 2024, in Scientific Reports, could eventually inform new treatment options for people who experience alcohol use disorder (AUD).
Company and financial neuro-rehab news
IV maintenance dosing for the treatment of early Alzheimer’s Disease
Eisai Co. and Biogen Inc. have announced that Eisai submitted to the U.S. Food and Drug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (LEQEMBI®) intravenous maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer’s disease in patients with mild cognitive impairment or mild dementia stage of disease.
Technology news
Next development stage of AI-Powered precision neuroscience
Manifest Technologies, developer of an AI-powered computational neuro-imaging platform for CNS disease, today unveiled the company after completing its initial funding and partnership with a top five global pharmaceutical company. The NAIO™ platform enables CNS pharmaceutical companies to use human neuroimaging to unlock quantitative indication and patient selection decisions for clinical trials, saving billions of dollars in clinical development. Manifest is actively working with Johnson & Johnson to deploy its solutions across several programmes.
